SCHEDULE: BlackRock Discloses 5.2% Stake in Alector, Inc.

BlackRock, Inc. has reported beneficial ownership of 5.2% of Alector, Inc.'s common stock as of March 31, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Alector, Inc. common stock.
• As of March 31, 2026, BlackRock beneficially owns 5,784,214 shares, representing 5.2% of the class of securities.
• The filing specifies that BlackRock, Inc. has sole voting power over 5,697,278 shares and sole dispositive power over 5,784,214 shares.
• This filing is made in accordance with Rule 13d-1(b) and BlackRock, Inc. is identified as a holder of securities in the ordinary course of business, not for the purpose of influencing control.
• The filing also includes a Power of Attorney dated January 21, 2025, appointing several individuals to execute filings on behalf of BlackRock, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership and does not inherently signal positive or negative performance for Alector, Inc. itself.

Positives

• BlackRock, a significant institutional investor, holds a substantial stake in Alector, Inc., which can be viewed as a positive signal of confidence in the company's prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a passive investment approach rather than an attempt to gain control.

Negatives

• The filing does not contain any negative financial results or operational challenges for Alector, Inc. itself, as it is a disclosure by a third-party investor.

Risks

• While not directly stated as a risk for Alector, Inc., a significant stake held by an institutional investor like BlackRock could lead to increased scrutiny or potential influence on corporate decisions.
• The Power of Attorney document, while standard, indicates a broad delegation of authority for filings, which could be a point of interest for governance-focused investors.

Future Outlook

The filing itself is a historical disclosure of ownership as of a specific date and does not contain forward-looking statements or guidance from Alector, Inc. or BlackRock regarding future performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
• "This power of attorney shall expressly revoke the power of attorney dated 30th day of April, 2023 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates."

Industry Context

StockSavvy.ai notes that BlackRock's filing of a Schedule 13G for Alector, Inc. is a routine disclosure for a major institutional asset manager. Such filings are common when an entity crosses the 5% ownership threshold in a publicly traded company. This indicates BlackRock's role as a significant, albeit passive, investor in the biotechnology or pharmaceutical sector where Alector operates.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing confirms BlackRock as a significant institutional shareholder, which can add stability and credibility to the company's investor base. However, it does not imply any direct action or benefit to other shareholders from this filing alone.
• Management: While BlackRock's investment is passive, its significant stake means Alector's management will be aware of their presence and may consider their perspective in strategic decisions.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• BlackRock will continue to monitor its investment in Alector, Inc. and may adjust its holdings based on market conditions and company performance.
• Alector, Inc. will continue its operations and disclosures as a publicly traded entity.

Key Dates

Keywords

Alector, Inc., BlackRock, Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Securities Exchange Act of 1934, Delaware, Investment Management